Market Cap 1.27B
Revenue (ttm) 983.71M
Net Income (ttm) -545.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 100.25
Profit Margin -55.41%
Debt to Equity Ratio 0.00
Volume 10,667,700
Avg Vol 3,975,120
Day's Range N/A - N/A
Shares Out 160.19M
Stochastic %K 35%
Beta 2.14
Analysts Sell
Price Target $16.00

Latest News on NVAX

Novavax to Participate in Jefferies London Healthcare Conference

Nov 13, 2024, 8:00 AM EST - 3 months ago

Novavax to Participate in Jefferies London Healthcare Conference


Novavax Q3 Earnings Disappoint, But A Turnaround May Be Underway

Nov 13, 2024, 7:30 AM EST - 3 months ago

Novavax Q3 Earnings Disappoint, But A Turnaround May Be Underway


Novavax, Inc. (NVAX) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 11:52 AM EST - 3 months ago

Novavax, Inc. (NVAX) Q3 2024 Earnings Call Transcript


Novavax Stock Dives Even Though Results Beat Forecasts

Nov 12, 2024, 9:44 AM EST - 3 months ago

Novavax Stock Dives Even Though Results Beat Forecasts


US FDA lifts clinical hold on Novavax's combo COVID-flu shot

Nov 11, 2024, 8:41 AM EST - 3 months ago

US FDA lifts clinical hold on Novavax's combo COVID-flu shot


Novavax, UK terminate vaccine supply agreement

Nov 5, 2024, 5:15 PM EST - 3 months ago

Novavax, UK terminate vaccine supply agreement